Powder: -20°C for 3 years | In solvent: -80°C for 1 year
PSMA-11 (HBED-CC-PSMA) detects prostate cancer recurrence and metastasis by binding to the extracellular structural domain of prostate-specific membrane antigen (PSMA).PSMA-11 is often used as a tracer of PSMA-expressing tumours in positron emission tomography (PET) scanning by intravenous injection of gallium Ga 68-labelled PSMA-11, Glu-urea-Lys(Ahx) molecule targeted and bound PSMA-expressing tumour cells. After internalisation, PSMA-expressing tumour cells could be detected on PET imaging.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 147.00 | |
5 mg | In stock | $ 372.00 | |
10 mg | In stock | $ 597.00 | |
25 mg | In stock | $ 935.00 | |
50 mg | In stock | $ 1,260.00 | |
100 mg | In stock | $ 1,690.00 |
Description | PSMA-11 (HBED-CC-PSMA) detects prostate cancer recurrence and metastasis by binding to the extracellular structural domain of prostate-specific membrane antigen (PSMA).PSMA-11 is often used as a tracer of PSMA-expressing tumours in positron emission tomography (PET) scanning by intravenous injection of gallium Ga 68-labelled PSMA-11, Glu-urea-Lys(Ahx) molecule targeted and bound PSMA-expressing tumour cells. After internalisation, PSMA-expressing tumour cells could be detected on PET imaging. |
Targets&IC50 | GCP II:0.012 µM(Ki), GCP III:0.013 µM(Ki) |
Synonyms | HBED-CC-PSMA, Psma-hbed-CC, PSMA11 |
Molecular Weight | 946.99 |
Formula | C44H62N6O17 |
CAS No. | 1366302-52-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 90.0 mg/mL (95.0 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
PSMA-11 1366302-52-4 PSMA 11 HBED-CC-PSMA Psma-hbed-CC PSMA11 inhibitor inhibit